LumiraDx Limited (LMDXF)
OTCMKTS: LMDXF · Delayed Price · USD
0.0170
+0.0016 (10.39%)
Apr 26, 2024, 3:56 PM EDT - Market closed
LumiraDx Revenue
LumiraDx had revenue of $126.52M in the twelve months ending June 30, 2023, down -68.25% year-over-year. Revenue in the quarter ending June 30, 2023 was $21.00M, a -53.04% decrease year-over-year. In the year 2022, LumiraDx had annual revenue of $254.48M, a decrease of -39.62%.
Revenue (ttm)
$126.52M
Revenue Growth
-68.25%
P/S Ratio
0.04
Revenue / Employee
$104,558
Employees
1,210
Market Cap
5.42M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 254.48M | -166.95M | -39.62% |
Dec 31, 2021 | 421.43M | 282.28M | 202.85% |
Dec 31, 2020 | 139.15M | 116.01M | 501.30% |
Dec 31, 2019 | 23.14M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionLMDXF News
- 4 months ago - LumiraDx Announces its Securities will be Suspended from Trading on Nasdaq at the Open of Business on January 9th - GlobeNewsWire
- 4 months ago - Roche to buy part of LumiraDx diagnostics platform for $295 million - Reuters
- 4 months ago - LumiraDx Announces Agreement to Sell its Cutting Edge Point of Care Technology Platform to Roche - GlobeNewsWire
- 6 months ago - LumiraDx Announces Receipt of NASDAQ Delisting Determination; Plans to Appeal - GlobeNewsWire
- 6 months ago - Top 4 Health Care Stocks That May Rocket Higher This Month - Generation Bio (NASDAQ:GBIO), Evelo Biosciences (NASDAQ:EVLO) - Benzinga
- 8 months ago - LumiraDx Reports Second Quarter 2023 Results - GlobeNewsWire
- 9 months ago - LumiraDx to Announce Second Quarter Financial Results and Host Quarterly Conference Call on August 24 - GlobeNewsWire
- 9 months ago - LumiraDx's Point of Care Diagnostics Group Continues Commercial Expansion Announcing a Distribution Agreement with Axonlab for its LumiraDx Platform and Tests - GlobeNewsWire